Evista (raloxifene) might help prevent breast cancer in postmenopausal women

March 1999

New research suggests that Evista (raloxifene) might help prevent breast cancer in postmenopausal women.

Women taking Evista for osteoporosis seem to have a 60% lower risk of developing breast cancer. This may turn out to be similar to the benefit that's seen with tamoxifen.

Tamoxifen REDUCES the incidence of breast cancer up to 50% in high-risk women...but it INCREASES the risk of endometrial cancer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote